116 completed, 32 unknown, 21 terminated, 14 recruiting. 110 Phase 2, 63 Phase 1, 19 Phase 3, 6 Phase 4, 3 Not applicable.
Follow Afatinib: new trials by email Literature Review of Afatinib trials Research Report on Afatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Exploratory Study of Inhaled Afatinib Dimaleate PK Profile Afatinib Dimaleat, inhalation of afatinib dimaleate - Lung Cancer, Oral Cancer | Phase 1 | Terminated | Petrov, Andrey | 4 | 2025-11-09 | 2026-06-03 |
| A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma Palbociclib, Afatinib(30mg), Afatinib(40mg) - Esophagus Cancer | Phase 1 / Phase 2 | Recruiting | West China Hospital | 45 | 2025-09-10 | 2025-12-03 |
| A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. Tislelizumab, Afatinib, Low dose radiotherapy - Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy | Phase 2 | Completed | West China Hospital | 98 | 2025-06-28 | 2026-06-30 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma Tislelizumab, Afatinib, Lysogenic HSV virus. - HNSCC, Lysogenic HSV Virus | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 29 | 2025-06-10 | 2026-07-01 |
| Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC Afatinib plus chemotherapy as conversion treatment - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Shandong Public Health Clinical Center | 30 | 2025-05-01 | 2025-07-17 |
| Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC Tislelizumab, Afatinib, Low dose radiotherapy - Head and Neck Cancer | Phase 2 | Withdrawn | West China Hospital | 2025-01-20 | 2025-11-19 | |
| A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus Lysogenic HSV virus., Tislelizumab, Afatinib - HNSCC, Lysogenic HSV Virus | Phase 1 | Withdrawn | West China Hospital | 2024-12-15 | 2026-10-16 | |
| Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Afatinib - Fanconi Anemia, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 25 | 2024-11-08 | 2026-05-27 |
| Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer Trastuzumab deruxtecan, Afatinib - Stomach Neoplasm | Phase 1 / Phase 2 | Recruiting | Jeeyun Lee | 61 | 2024-09-30 | 2025-12-15 |
| Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma Tislelizumab, Afatinib, Low dose radiotherapy - Head and Neck Cancer | Phase 1 | Completed | West China Hospital | 9 | 2024-07-31 | 2025-12-29 |
| Pemigatinib + Afatinib in Advanced Refractory Solid Tumors Afatinib, Pemigatinib - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 | Recruiting | Massachusetts General Hospital | 32 | 2024-04-17 | 2026-09-23 |
| Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations Afatinib 40 MG - NSCLC | Phase 2 | Recruiting | National University Hospital, Singapore | 35 | 2024-03-25 | 2025-07-24 |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients Nintedanib, gefitinib, erlotinib, afatinib, osimertinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Recruiting | China Medical University Hospital | 20 | 2024-02-23 | 2025-01-23 |
| Pilot Trial for Treatment of Recurrent Glioblastoma Afatinib, Dasatinib, Palbociclib - Glioblastoma, Recurrent Disease | Early Phase 1 | Recruiting | AHS Cancer Control Alberta | 10 | 2023-06-27 | 2025-04-25 |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction Palbociclib, Afatinib - Esophagus Squamous Cell Carcinoma | Phase 2 | Unknown | AIPING ZHOU | 30 | 2023-04-06 | 2023-05-18 |
| To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC Afatinib, Irinotecan - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Peking University | 72 | 2023-02-09 | 2023-04-19 |
| Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets - NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Terminated | Partner Therapeutics, Inc. | 13 | 2022-11-17 | 2026-04-27 |
| Observational Study of Afatinib 30 mg Daily Afatinib - Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor Mutation | Unknown | National University Hospital, Singapore | 69 | 2022-10-25 | 2024-05-17 |
Showing 20 of 208. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (68) · Neoplasms (25) · Breast Neoplasms (15) · Squamous Cell Carcinoma of Head and Neck (13) · Lung Neoplasms (12) · Head and Neck Neoplasms (11) · Neoplasm Metastasis (8) · Carcinoma, Squamous Cell (7) · Colorectal Neoplasms (6) · Esophageal Squamous Cell Carcinoma (6) · Pancreatic Neoplasms (6) · Stomach Neoplasms (5) · Esophageal Neoplasms (4) · Multiple Myeloma (4) · Prostatic Neoplasms (4)
Boehringer Ingelheim (80) · West China Hospital (8) · Massachusetts General Hospital (4) · Peking University (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · National Taiwan University Hospital (3) · National University Hospital, Singapore (3) · Samsung Medical Center (3) · The Netherlands Cancer Institute (3) · Yonsei University (3) · Guangdong Association of Clinical Trials (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Instituto Nacional de Cancerologia de Mexico (2)
United States (55) · China (37) · Germany (27) · France (26) · South Korea (23) · United Kingdom (23) · Spain (21) · Taiwan (20) · Italy (17) · Belgium (15) · Canada (14) · Netherlands (14) · Singapore (11) · Austria (10) · Japan (10)
Xingchen Peng, Professor (3) · George Simon, MD (2) · Lin Shen, Professor (2) · Volker Heinemann, Professor (2) · Xingchen Peng (2) · Yongfeng Yu, Master (2) · AJ Gelderblom, Prof (1) · Aarti Bhatia, MD, MPH (1) · Albiruni Razak, M.D. (1) · Alessandro Santin, M.D. (1) · Anne Hansen Ree, Prof. MD PhD (1) · Ben Creelan, M.D. (1)
PMID 25589191, PMID 26051236, PMID 29653820, PMID 23816960, PMID 26823294, PMID 27601237, PMID 35046059, PMID 11099318, PMID 11948464, PMID 12006548, PMID 15258838, PMID 15746676, PMID 15894362, PMID 16805854, PMID 16990388, PMID 17150016, PMID 18245491, PMID 18612161, PMID 19624979, PMID 20156778, PMID 20179235, PMID 20818862, PMID 21215350, PMID 21488898, PMID 21499124, PMID 21670455, PMID 21844012, PMID 22071596, PMID 22271810, PMID 22325357, PMID 22452895, PMID 22452896, PMID 22960745, PMID 23359684, PMID 23552882, PMID 23554766, PMID 23636398, PMID 23816963, PMID 23816967, PMID 23937717, PMID 2406000, PMID 24439929, PMID 24714359, PMID 24868099, PMID 25037863, PMID 25057165, PMID 25074459, PMID 25268372, PMID 25299645, PMID 25305457
2009 (8), 2008 (7), 2014 (3), U10CA180820 (3), 2015 (2), U24CA196172 (2), 2016 (1), 2017 (1), 2019 (1), 2023 (1), P30CA014599 (1), P30CA093373 (1), U10CA021115 (1), U10CA180888 (1)